Geoff Gilmartin, M.D.

Dr. Geoff Gilmartin serves as Chief Medical Officer at Expedition Therapeutics, bringing over a decade of leadership in clinical development. He previously led the Phase 3 Fasenra (benralizumab) program at AstraZeneca, advancing therapies across respiratory and rare disease indications. Earlier, Dr. Gilmartin held positions of increasing responsibility at Vertex Pharmaceuticals, where he was the medical lead for the Kalydeco (ivacaftor) clinical program and helped initiate pivotal Phase 3 trials that supported multiple label expansions. He also served as Chief Development Officer and later Chief Medical Officer at Proteostasis Therapeutics, guiding its cystic fibrosis program from preclinical research through Phase 2. A pulmonary and critical care physician by training, Dr. Gilmartin continues to serve as an attending physician in the intensive care unit at Beth Israel Deaconess Medical Center. He earned his B.A. in History from Dartmouth College, his M.D. from Brown University School of Medicine, and his Master of Medical Science in Clinical Research from Harvard Medical School.